Table 2.

Anticancer effect of cardiac glycosides against different cancer cell lines.

Cancer Type	Cardiac Glycosides Used	Cell Lines	Reference
Breast	digitoxin, digoxin, ouabain, oleandrin, proscillaridin A, convallatoxin, bufalin, lanatoside C, strophanthidin, peruvoside	MCF-7, MDA-MB-231, MDA-MB-435	[79,84,88,99,106,120,126,127,131]
Cervical	digoxin, oleandrin, convallatoxin,	HeLa	[86,99,105]
Colon	oleandrin, convallatoxin, neriifolin, gitoxigenin, lanatoside C, strophanthidin,	SW480, HCT116, RKO, HT-29	[96,104,124]
Leukemia	digitoxin, UNBS1450, bufalin, peruvoside	K562, U937, HEL, MOLT-4, REH, MEG-01, HL60, TF-1, KBM5, ML-1, KG1a	[82,89,102,110,111,112,113,128,132]
Liver	digoxin, cinobufagine, proscillaridin A, lanatoside C, neriifolin, strophanthidin, peruvoside	Hep3B, HA22T, Huh-7, HepG2, Mahlavu, FOCUS	[15,45,49,123,126,127,133,134]
Lung	digitoxin, digoxin, ouabain, proscillaridin A, UNBS1450, bufalin, glucoevatromonoside, lanatoside C, strophanthidin, peruvoside	A427, A549, Calu-1, H1355, H1975, H292, HCC827, NCI-H358, SK-LU-1	[15,53,71,72,78,85,90,101,107,108,118,119,126,127,134,135]
Osteosarcoma	oleandrin, proscillaridin A, bufalin	U-2 OS, Saos-2, 143B	[98,103,121]
Pancreatic	oleandrin, bufalin	PANC-1, BXPC-3, MIA PaCa-2, CFPAC-1, SW1990	[97,114,115,116]
Prostate	anvirzel, digitoxin, digoxin, ouabain, oleandrin, proscillaridin A, bufalin, cinobufagine	PC3, C4-2, DU-145, LNCaP	[76,83,87,94,100,109]